Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $3.8571.

RVPH has been the subject of a number of research reports. D. Boral Capital restated a “buy” rating and set a $2.00 price objective on shares of Reviva Pharmaceuticals in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday. Benchmark lowered their price objective on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a research report on Monday, September 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday.

Reviva Pharmaceuticals Stock Up 10.4%

Shares of NASDAQ:RVPH opened at $0.31 on Friday. The company’s fifty day moving average is $0.55 and its two-hundred day moving average is $0.51. The company has a market cap of $35.31 million, a P/E ratio of -0.67 and a beta of -0.02. Reviva Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $2.17.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, November 13th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.05. Equities research analysts anticipate that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of RVPH. Geode Capital Management LLC increased its position in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares during the last quarter. NewEdge Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals during the 1st quarter worth about $58,000. XTX Topco Ltd acquired a new position in shares of Reviva Pharmaceuticals during the 2nd quarter valued at about $31,000. Lido Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals during the 3rd quarter valued at about $37,000. Finally, Millennium Management LLC raised its stake in shares of Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after acquiring an additional 223,178 shares in the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.